Sinovac Biotech Ltd (SVA) stock
SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.47+0.00 (0.00%)
Close on Nov 13, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $216.18M, down 20.1% from the year before. Over ten years it grew 36.7% a year on average. The highest annual figure on record is $478.69M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $216.18M | -20.1% |
| FY2024 | Dec 31, 2024 | $270.66M | -22.7% |
| FY2023 | Dec 31, 2023 | $350.19M | -26.8% |
| FY2022 | Dec 31, 2022 | $478.69M | +213.5% |
| FY2021 | Dec 31, 2021 | $152.70M | +213.2% |
| FY2020 | Dec 31, 2020 | $48.76M | +101.0% |
| FY2019 | Dec 31, 2019 | $24.25M | +10.7% |
| FY2018 | Dec 31, 2018 | $21.91M | +6.9% |
| FY2017 | Dec 31, 2017 | $20.49M | +62.0% |
| FY2016 | Dec 31, 2016 | $12.65M | +33.3% |
| FY2015 | Dec 31, 2015 | $9.49M | -13.2% |
| FY2014 | Dec 31, 2014 | $10.93M | +34.5% |
| FY2013 | Dec 31, 2013 | $8.13M | -52.3% |
| FY2012 | Dec 31, 2012 | $17.04M | +89.2% |
| FY2011 | Dec 31, 2011 | $9.01M | +5.9% |
| FY2010 | Dec 31, 2010 | $8.51M | +93.1% |
| FY2009 | Dec 31, 2009 | $4.41M | – |
See a number that looks wrong?